Golden, Colorado 80401

  • induced Osteomalacia (TIO)


The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.

Study summary:

Enrolled patients may or may not be treated with commercially available burosumab during the TIO DMP at the discretion of their treating physician. Given the observational nature of the TIO DMP, specific treatments or supportive management will not be provided as part of the study.


Inclusion Criteria: - Have a clinical diagnosis of TIO based on the presence of an underlying PMT (confirmed by imaging) AND/OR historical documentation. Note: For adult patients with TIO in whom the causative PMT has never been located, and all pediatric patients, documented evidence of negative genetic testing for other hereditary hypophosphatemic disorders is necessary - For patient safety, all participating female patients of child-bearing potential must be willing to have pregnancy tests prior to certain assessments performed as part of the DMP - Be willing to provide access to prior medical records including tumor pathology reports and biopsy slides, imaging, biochemical, and diagnostic, medical, and surgical history data, if available - Be willing and able to provide informed consent after the nature of the study has been explained, and prior to any research-related procedures - Be willing and able to comply with the study visit schedule and study procedures Exclusion Criteria: - Have a clinical diagnosis of TIO deemed to be caused by a tumor other than a PMT - Serious medical or psychiatric comorbidity that, in the opinion of the Investigator, would present a concern for patient safety or compromise the ability to provide consent or comply with the study visit schedule and study procedures - Less than 1 year of life expectancy (for any cause) in the opinion of the Investigator - Concurrent enrollment in a clinical trial without prior approval from the TIO DMP Sponsor - Undergoing treatment with burosumab for an unapproved indication



Primary Contact:

Study Director
Medical Director
Ultragenyx Pharmaceutical Inc

Patients Contact: Patient Advocacy
Phone: 1-415-483-8800

Backup Contact:

HCPs Contact: Medical Information
Phone: 1-888-756-8657

Location Contact:

Golden, Colorado 80401
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.